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Abstract To investigate the prevalence of fatigue, day-
time sleepiness, reduced sleep quality, and restless legs
syndrome (RLS) in a large cohort of patients with Charcot-
Marie-Tooth disease (CMT) and their impact on health-
related quality of life (HRQoL). Participants of a web-based
survey answered the Epworth Sleepiness Scale, the Pitts-
burgh Sleep Quality Index, the Multidimensional Fatigue
Inventory, and, if the diagnostic criteria of RLS were met,
the International RLS Severity Scale. Diagnosis of RLS was
afﬁrmed in screen-positive patients by means of a stan-
dardized telephone interview. HRQoL was assessed by
using the SF-36 questionnaire. Age- and sex-matched
control subjects were recruited from waiting relatives of
surgical outpatients. 227 adult self-reported CMT patients
answered the above questionnaires, 42.9% were male, and
57.1% were female. Age ranged from 18 to 78 years.
Compared to controls (n = 234), CMT patients reported
signiﬁcantly higher fatigue, a higher extent and prevalence
of daytime sleepiness and worse sleep quality. Prevalence
of RLS was 18.1% in CMT patients and 5.6% in controls
(p = 0.001). RLS severity was correlated with worse sleep
quality and reduced HRQoL. Women with CMT were
affected more often and more severely by RLS than male
patients. With regard to fatigue, sleep quality, daytime
sleepiness, RLS prevalence, RLS severity, and HRQoL, we
did not ﬁnd signiﬁcant differences between genetically
distinct subtypes of CMT. HRQoL is reduced in CMT
patients which may be due to fatigue, sleep-related symp-
toms, and RLS in particular. Since causative treatment for
CMT is not available, sleep-related symptoms should be
recognized and treated in order to improve quality of life.
Keywords Charcot-Marie-Tooth disease  Fatigue 
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Introduction
Charcot-Marie-Tooth disease (CMT) refers to a heteroge-
nous group of monogenetic peripheral neuropathies with an
overall prevalence of 1:2,500 [1]. Classiﬁcation of CMT is
based on clinical and electrophysiological ﬁndings, the trait
of inheritance, and the underlying genetic cause. To date,
40 genes and gene loci have been associated with CMT [2].
Distal motor weakness and muscle atrophy, foot deformi-
ties, gait disturbances and sensory impairment are the
clinical hallmarks of CMT. For self-reporting of CMT
subtypes the following options were offered: CMT1,
CMT2, CMTX and ‘‘other’’. Many CMT patients report
fatigue, daytime sleepiness, and non-restorative sleep
[3, 4]. Sleep disturbances may be associated with pares-
thesia, muscle cramps, or restless legs syndrome (RLS). In
a study with 44 participants, RLS was present in 37% of
CMT2 patients and 0% of CMT1 patients [5]. Recently,
RLS was found to be reported by 16.1% of CMT2 and
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sleep in CMT may be associated with phrenic neuropathy
and diaphragmatic weakness [7, 8]. Sleep apnea was found
to be common in CMT patients, and the apnea-hypopnea-
index (AHI) correlated with disease severity [9, 10]. The
objective of the present study was to determine the prev-
alence of fatigue, daytime sleepiness, reduced sleep quality
and RLS in CMT patients and their impact on health-
related quality of life (HRQoL).
Methods
Data were collected by means of an anonymized, web-
based survey which was made accessible exclusively to
persons registered with the only German internet forum for
CMT patients [11]. Registered subjects were invited to
participate by the responsible webmaster via e-mail. It was
made impossible to take part more than once. The study
was approved by the local ethics committee. Participants
were asked whether the diagnosis of CMT had been made
by a specialized neurologist, and whether it had been
genetically conﬁrmed. For self-reporting of CMT subtypes
the following options were offered: ‘‘CMT1 (PMP22 or
MPZ gene)’’, ‘‘CMT2 (Mitofusin-2 or other genes)’’,
‘‘CMTX (GJB1 gene)’’, and ‘‘other/unclassiﬁed CMT’’, the
latter including participants without genetically proven
diagnoses. Participants were asked for age, gender, height,
and weight. In addition, they answered six questionnaires
in the German language. The Epworth Sleepiness Scale
(ESS) is an eight-item self-reporting tool to measure day-
time sleepiness [12], with a score ranging from 0 to 24. A
cut-off score [10 is considered pathological [13]. The
Pittsburgh Sleep Quality Index (PSQI) focusses on the
quality of sleep during the last 4 weeks [14]. It comprises
seven component scores reﬂecting sleep latency, sleep
duration, habitual sleep efﬁciency, sleep disturbances, use
of sleeping medication, daytime dysfunction, and overall
sleep quality. The global PSQI score has a range of 0–21. A
cut-off score of 5 is considered to allow reliable distinction
between ‘‘good sleepers’’ (B5) and ‘‘bad sleepers’’ ([5,
[15]). Fatigue was assessed using the Multidimensional
Fatigue Inventory (MFI-20) which covers ﬁve dimensions
of fatigue: general, physical, and mental fatigue, reduced
activities, and reduced motivation [16]. The German ver-
sion is based on a 5-point scale, resulting in a global score
of 20–100, with a higher score indicating more severe
fatigue [17]. RLS is a clinical diagnosis [18]. Participants
answered standardized questions covering the diagnostic
criteria of RLS as deﬁned by the International Restless
Legs Syndrome Study Group (German translation validated
by [19]). In addition, we asked for any current medication
and concomitant diseases possibly promoting RLS, fatigue,
or breathing disorders during sleep. The respective list
included known obstructive sleep apnea (OSA), chronic
obstructive pulmonary disease, chronic renal failure, con-
gestive heart failure, multiple sclerosis, iron deﬁciency,
malignancy, and diabetes mellitus. Participants meeting the
diagnostic criteria for RLS were contacted by e-mail, and
then received a telephone call for conﬁrmatory diagnostic
evaluation by a movement disorder specialist (M. B.). The
structured telephone interview was performed using the
same RLS questionnaire, clarifying whether each diag-
nostic symptom was truly present. The interview was
designed in accordance with a previously validated English
diagnostic telephone interview for RLS [20]. Patients
screen-positive for RLS were asked for any speciﬁc med-
ication and answered the International RLS Severity Scale
(IRLS, [21, 22]) which allows discrimination of four RLS
severity grades: mild (score 0–10), moderate (score 11–20),
severe (score 21–30), and very severe (score 31–40). The
SF-36 questionnaire [23] yields scores for eight domains of
HRQoL: physical functioning, physical role limitation,
physical pain, general health perception, vitality, social
functioning, emotional role limitation, and mental health
perception. Physical and mental component summary
scales (PCS and MCS) are calculated from the subscales
and transformed to a normalized T-score with a mean of 50
and standard deviation of 10 [23]. Higher scores represent
better quality of life. German versions of the ESS, the
PSQI, the MFI-20 and the SF-36 have been validated [24–
29]. With the exception of the MFI-20 and the SF-36, all
questionnaires of the survey were also answered by 234
age- and sex-matched control subjects who were recruited
from waiting relatives of surgical patients visiting a trau-
matology outpatient clinic. As a random sample, this
population was drawn from 411 controls we previously
published [30].
Statistical analysis
The survey was conducted using GrafStat
 software [31].
Data analysis was performed using SPSS
 v.15.0. Normal
distribution of continuous variables was tested using
the Kolmogorov–Smirnov test. Student’s t test and the
Mann–Whitney U test were used to compare the means of
parametric or non-parametric variables, respectively. Differ-
ences among categorical variables were analysed using the
v
2 test or the two-tailed Fisher’s exact test as appropriate.
For differences between groups, pairwise ANOVA with
Bonferroni correction was applied. Spearman correlation
coefﬁcients were used to examine associations between
continuous variables. p Values \0.05 were considered
statistically signiﬁcant. Multiple linear regression analysis
was performed to test whether age and sex were
J Neurol (2010) 257:646–652 647
123independently associated with MCS and PCS scores.
Multivariate analysis was carried out to examine the
association between the IRLS score and PCS or MCS
scores while controlling for age, sex and the MFI-20, ESS,
and PSQI scores. In order to limit the number of regres-
sions, the MCS and PCS scores, rather than the individual
SF-36 domains, were used as main outcome variables.
Results
247 adult survey participants reported having been diag-
nosed with CMT by a specialized neurologist. 20 of them
incompletely answered at least one of the questionnaires
and were excluded from further analysis. Of the remaining
227 individuals, 42.9% were male, and 57.1% were female.
Patients were 18 to 78 years old (mean 42.1 years, SD
11.6 years). The mean body mass index (BMI) was 23.7
(SD 6.8). Both age and BMI were normally distributed.
Representation of self-reported CMT subtypes in the study
population was as follows: CMT1 49.3%, CMT2 15.9%,
CMTX 4.0%, ‘‘other and unclassiﬁed CMT’’ 30.8%.
Concomitant diseases were speciﬁed by 21 (9.3%) of CMT
patients. In the control group, mean age was 42.0 years
(SD 12.9). 64.5% of control subjects were female, and
35.5% were male.
Fatigue
Mean and standard deviations of the MFI-20 total score
and subscores are depicted in Table 1. Genetically distinct
CMT subgroups did not differ signiﬁcantly (Table 2). In
CMT patients, we found a weak but signiﬁcant correlation
between age and the General Fatigue subscore (GFS,
r = 0.13, p\0.05). Neither age nor sex correlated with
the MFI-20 total score or any of the other subscores. Since
the GFS may serve as an overall indicator of fatigue [16], a
cut-off value of 12 is considered to indicate severe fatigue
in cancer patients [32]. The GFS was 12 or above in 98
(43.2%) of the study’s CMT patients. Patients with con-
comitant disease were analyzed separately. Mean MFI-20
total score and subscores were not signiﬁcantly increased.
However, the percentage of severely fatigued patients in
this subgroup was 73.6%. Compared to data obtained from
the literature, the MFI-20 global score and the different
subscores each were higher in self-reported CMT patients
than in a cohort of healthy elderly people ([60 years)
drawn from the normal population (Table 1,[ 17]).
Daytime sleepiness
Mean ESS score was 8.8 (SD 4.1) in CMT patients and 6.5
(SD 3.2) in control subjects (p\0.001). Pathological
daytime sleepiness as indicated by an ESS score[10 was
reported by 31.7% of CMT patients and 11.8% of non-
CMT controls (p\0.001). Differences between geneti-
cally distinct subgroups were not signiﬁcant (Table 2). Age
and sex were not correlated with the ESS total score.
Multiple regression analysis showed that the presence of
CMT was not a signiﬁcant predictor of excessive daytime
sleepiness (data not shown).
Reduced sleep quality
79.3% of CMT patients and 17.2% of controls turned out to
be ‘‘bad sleepers’’ as indicated by a global PSQI above 5
(p\0.001). A PSQI global score [5 was found with a
prevalence of 80.4% in the CMT1 group, 72.2% in the
CMT2 group, 88.9% in the CMTX group, and 80.0% in the
‘‘other/unclassiﬁed CMT’’ subgroup. Mean PSQI global
Table 1 Self-reported fatigue in CMT patients
Present study (1)
Study population CMT1, CMT2, CMTX
(with known genetic diagnosis)
Other/unclassiﬁed
CMT
All CMT
patients
CMT and concomitant
disease
Elderly
n 157 70 227 21 622
Age (mean and SD) 41.5 (11.0) 42.2 (12.5) 41.2 (12.6) 50.4 (8.6) 69.6 (6.8)
MFI-20 global score 60.2 (5.1) 59.5 (4.6) 60.2 (4.9) 60.6 (3.9) 50.6 (16.9)
General fatigue 11.1 (2.0) 11.1 (1.7) 11.2 (1.9) 11.8 (2.2) 10.6 (3.8)
Physical fatigue 12.9 (1.8) 12.6 (1.6) 12.8 (1.8) 12.3 (1.9) 10.8 (4.3)
Mental fatigue 11.4 (1.8) 11.5 (1.7) 11.4 (1.8) 11.8 (1.9) 9.0 (3.5)
Reduced activities 12.7 (1.7) 12.2 (1.7) 12.6 (1.7) 12.5 (2.0) 10.5 (4.1)
Reduced motivation 12.0 (2.3) 12.1 (2.5) 12.2 (2.3) 12.3 (2.6) 9.6 (3.4)
Self-reported fatigue in CMT patients. Numbers depict mean and standard deviation (SD) of the MFI-20 global and domain scores. Patients with
CMT and concomitant disease reached even higher scores. For comparison, the far right column (1) shows data obtained from 622 elderly people
([60 years) in the German general population [17]. Data obtained from patients who identiﬁed themselves as genetically diagnosed with CMT1,
CMT2 or CMTX were combined since ANOVA analysis did not show any differences between these subgroups (Table 2)
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123score was 7.9 (SD 2.8) in all CMT patients and 3.7 (SD
2.3) in the control group (p\0.001). Differences between
genetically distinct subgroups were not signiﬁcant
(Table 2). Six out of seven component scores were sig-
niﬁcantly higher in CMT patients than in controls
(p\0.001, Table 3). Age and sex did not correlate with
the global PSQI or any of the component scores. Multiple
regression analysis including both CMT and control sub-
jects revealed CMT as the only signiﬁcant predictor of
reduced sleep quality independent from age and sex
(p\0.001).
RLS and RLS severity
47 (21.9%) self-reported CMT patients and 13 (5.6%)
control subjects were screen-positive for RLS (p\0.001).
Diagnosis of RLS was conﬁrmed by personal interview in
41 of the screen-positive CMT patients. The resulting
prevalence of RLS among all CMT patients was 18.1%,
which was still signiﬁcantly higher than in the control
group (p\0.001). The prevalence of RLS was 22.3% in
the CMT1 group, 19.4% in the CMT2 group, and 12.9% in
the ‘‘other/unclassiﬁed CMT’’ subgroup (n. s., Table 2).
Table 2 Intergroup analyses among genetically distinct CMT subgroups
CMT1 CMT2 CMTX p value
n 112 36 9 –
Age 42.2 (11.1) 41.6 (12.0) 43.9 (9.9) 0.81*
Females (%) 83.3 57.1 0 0.29
#
Fatigue (MFI-20 global score) 60.9 (5.1) 59.4 (4.2) 58.2 (6.3) 0.10*
Daytime sleepiness (ESS score) 9.2 (4.1) 8.6 (4.0) 6.2 (4.2) 0.10*
ESS[10 (%) 38.4 30.6 33.3 0.73
#
Reduced sleep quality (PSQI global score) 8.1 (2.9) 7.6 (2.8) 7.8 (2.4) 0.84*
PSQI[5 (%) 80.4 72.2 88.9 0.68
#
RLS prevalence (%) 22.3 19.4 11.1 0.83
#
RLS severity (IRLS score) 20.7 (6.2) 21.2 (4.9) 16.0 0.10*
Differences between the CMT1, CMT2, and CMTX subgroups with regard to all outcomes of interest. Numbers are depicted as mean and SD or
percentage as indicated. p Values\0.05 were considered signiﬁcant. Statistical analysis was carried out using ANOVA with Bonferroni’s
correction (*) or Pearson’s Chi-square test (#), respectively. In the CMTX group, only one patient had RLS
Table 3 PSQI global and component scores of self-reported CMT patients and control subjects
Present study (1)
CMT1, CMT2, CMTX
(with known genetic diagnosis)
Other/unclassiﬁed
CMT
All CMT
patients
CMT and
concomitant disease
Controls
n 157 70 227 21 234 1,049
Age 41.5 (11.0) 42.2 (12.5) 41.2 (12.6) 50.4 (8.6) 42.0 (12.9) 41.9
PSQI global score 8.0 (2.8) 7.8 (2.8) 7.9 (2.8) 8.7 (3.4) 3.7 (2.3) 4.6 (3.7)
Sleep quality 1.4 (0.7) 1.4 (0.7) 1.4 (0.7) 1.6 (0.9) 0.7 (0.6) 0.8 (0.8)
Sleep latency 1.6 (0.9) 1.4 (0.9) 1.5 (0.9) 1.6 (1.0) 0.6 (0.7) 0.9 (0.9)
Sleep duration 1.0 (0.7) 0.8 (0.7) 0.9 (0.7) 1.3 (1.1) 0.6 (0.7) 0.7 (0.7)
Sleep efﬁciency 0.9 (1.0) 0.9 (1.1) 0.9 (1.0) 1.1 (1.2) 0.3 (0.7) 0.3 (0.7)
Sleep disturbances 1.5 (0.6) 1.4 (0.6) 1.5 (0.6) 1.7 (0.7) 0.9 (0.4) 0.8 (1.0)
Sleep medication 0.1 (0.3) 0.2 (0.6) 0.1 (0.4) 0.0 (0.0) 1.3 (0.1) 0.2 (0.7)
Daytime dysfunction 1.6 (0.7) 1.6 (0.7) 1.6 (0.7) 1.5 (0.8) 0.7 (0.6) 0.8 (0.8)
PSQI global and component scores of self-reported CMT patients and control subjects. The far right column (1) shows data obtained from a large
cohort of the Austrian normal population using the German version of the PSQI [28]. Numbers depict mean and standard deviation (in brackets).
In CMT patients, PSQI global score and 6 out of the 7 component scores were signiﬁcantly higher than in control subjects (numbers are printed in
bold, p\0.001). Patients with CMT and concomitant disease reached even higher scores on the PSQI. Data obtained from patients who
identiﬁed themselves as genetically diagnosed with CMT1, CMT2 or CMTX were combined since ANOVA analysis did not show any
differences between these subgroups
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123Only one out of nine CMTX patients had RLS. Mean onset
of RLS symptoms was at 27.7 years of age, with a range
from 4 to 61 years. RLS was most common in participants
above 60 years of age (23.5%), compared to 21.3% in the
30–60 years group and 16.7% in patients under 30 years
(n.s.). 24.6% of women and 15.5% of men had RLS
(p = 0.09). Women made up the majority of CMT patients
with RLS (68.1%), and they reached signiﬁcantly higher
IRLS scores than men (20.7 vs. 16.0, p\0.05). In the
CMT group, severity of RLS was not age-dependent (data
not shown). 20 out of 41 CMT patients with RLS (48.8%)
speciﬁed that they had been taking anticonvulsants, anti-
depressants, or L-DOPA for more than 6 months. 12.2%
reported receiving iron supplementation for proven iron
deﬁciency. All RLS patients on medication reported a
decrease of RLS symptoms after the onset of drug therapy.
However, the mean IRLS score was only slightly lower in
patients on symptomatic treatment than in patients without
any speciﬁc medication (data not shown).
Intercorrelation of fatigue, reduced sleep quality,
daytime sleepiness, and RLS
We did not ﬁnd signiﬁcant correlations between either the
MFI-20 and ESS scores or the MFI-20 and PSQI scores in
CMT patients (data not shown). Impaired sleep quality
(PSQI) and daytime sleepiness (ESS) were not signiﬁcantly
correlated in the entire CMT group (r = 0.12, p = 0.55),
the non-RLS subgroup (r = 0.29, p = 0.13), or in the
subset of patients with both CMT and RLS (r = 0.15,
p = 0.33). However, ESS and PSQI were signiﬁcantly
correlated (r = 0.51, p = 0.02) in female CMT patients
with RLS. Severity of RLS symptoms and global PSQI
were signiﬁcantly correlated (r = 0.43, p\0.05) in CMT
patients with RLS. This correlation was based on the
female patients alone (r = 0.54, p = 0.02). The IRLS
score showed no correlation with the MFI-20 global score
or the ESS score, respectively.
Impact of fatigue and sleep-related symptoms
on quality of life
Among self-reported CMT patients, the lowest SF-36
subscores were found for the vitality domain score (38.0,
SD 19.4) and the physical component score (PCS, 34.4, SD
10.8). Bivariate analysis showed that global PSQI and ESS
scores each were inversely correlated with four of the SF-
36 subscores (see Table 4, supplemental data). The MFI-20
total score was inversely correlated only with the physical
functioning index. In patients with both CMT and RLS, we
found a strong inverse correlation between RLS severity
and the physical functioning index, the role-physical score,
and the PCS (r values -0.56, -0.64, -0.66, p values
\0.01). Inverse correlation between RLS severity and the
mental health perception, vitality, and social functioning
indices was also signiﬁcant (r values -0.46, -0.42, and
-0.43, p values \0.05). Multivariate analysis was per-
formed separately for CMT patients with and without RLS.
We did not ﬁnd any signiﬁcant predictors for SF-36 MCS
in both groups. In patients with RLS, the signiﬁcant inde-
pendent predictors of SF-36 PCS were age (b =- 0.33,
p\0.01), ESS score (b =- 0.19, p\0.05), and the IRLS
score (b =- 0.66, p\0.01). In this subgroup, the IRLS
score remained a signiﬁcant independent predictor of the
PCS after controlling for age, sex, PSQI, ESS, and MFI-20
scores (b =- 0.5, p\0.05). In CMT patients without
RLS, only age was a signiﬁcant predictor of the PCS
(b =- 0.43, p\0.01).
Discussion
We present here the results of a survey on fatigue, sleep
quality, RLS, and HRQoL in a large cohort of self-reported
CMT patients. Prior studies focussed on either fatigue
[3, 33], RLS [5, 6] or daytime sleepiness [4] in smaller
numbers of patients. Using the Checklist Individual
Strength (CIS), Kalkman et al. [3] reported severe fatigue
in 64% of 137 CMT1A patients. Based on the GFS of the
MFI-20, we found severe fatigue in 43.2% of survey par-
ticipants. The use of different scoring tools may explain
this variation. In accordance with the study mentioned, we
did not ﬁnd a correlation between age and the MFI-20
global score. Compared to previous studies on fatigue in
the general population, CMT patients of all subgroups
showed higher MFI-20 subscores than people above
60 years of age [17]. Whereas age correlates with fatigue in
the general population [29], it is apparently not a major
factor contributing to fatigue in CMT patients. However,
the GFS was signiﬁcantly correlated with age, which pos-
sibly reﬂects that the progressive course of CMT takes its
toll in older patients. Little is known about the mechanisms
by which peripheral neuropathy leads to fatigue. It might
be explained by walking difﬁculties due to motor weak-
ness, foot deformities, and loss of proprioceptive control.
However, some patients report fatigue in the presence of
rather mild neurological disability. Our results suggest that
in CMT, fatigue is not correlated with poor sleep or day-
time sleepiness. It has been postulated that fatigue and
daytime sleepiness are different entities both caused by
non-restorative sleep [13], and our ﬁndings are in accor-
dance with previous reports showing that in multiple
sclerosis, for example, only a subset of ESS items is cor-
related with fatigue [34].
The prevalence of impaired sleep and excessive daytime
sleepiness is extraordinarily high in self-reported CMT
650 J Neurol (2010) 257:646–652
123patients, with no signiﬁcant differences between genetic
subtypes. Thus, our study cannot verify the assumption that
sleep quality is worse in CMT2 patients possibly due the
higher prevalence of RLS in this group previously reported
by Gemignani et al. [5]. Difﬁculties in falling asleep and
frequent awakenings appear to be the most important rea-
sons for non-restorative sleep in CMT patients. Our data
suggest that many of them suffer from RLS. We found the
overall prevalence of RLS in CMT patients to be 18.1%,
which is similar to numbers recently reported by Hattan
et al. [6]. Whereas Hattan et al. [6] found the highest
proportion of RLS-positive patients in individuals with
sensory and autonomous neuropathy (HSAN), this sub-
group cannot be identiﬁed in our study population. In
contrast to previous studies [5, 6] we found patients with
CMT1 slightly more often affected by RLS than CMT2
patients, and the genetic subtype did not signiﬁcantly
inﬂuence RLS severity. These ﬁndings may in part be
explained by two reasons: First, in our study, 83.3% of
CMT1 patients and only 57.1% of CMT2 patients were
female, and prevalence of RLS was about 10% higher in
women than in men. Second, albeit primary axonal damage
probably predisposes to RLS more than demyelination
[35], patients with demyelinating neuropathy do experience
secondary axonal degeneration, and there is a close rela-
tionship between axonal loss and disability [36]. Among 20
CMT1 patients, Hattan et al. [6] reported a 10% prevalence
of RLS, which is only half of what we found in 112 indi-
viduals. Since Hattan et al. did not provide epidemiological
data on the CMT patients included in their study, it may be
assumed that variations in age and sex distribution partially
account for this difference. For reasons to be clariﬁed,
female CMT patients were affected by RLS more often and
more severely than men, and the impact of RLS on sleep
quality was higher in women.
Daytime sleepiness in CMT has been addressed by
two studies using CMT1A patients as a control group
for patients with myotonic dystrophy (MD) [4, 33].
Rubinsztein et al. [33] reported CMT1A patients to be
less affected by daytime sleepiness than MD patients, and
none of them scored [10 on the ESS. Phillips et al. [4]
found 5 out of 13 CMT patients reached an ESS score
[10, and mean ESS score was 10.5. In our study popu-
lation, with mean age lower and probably less affected
persons included, the mean ESS score was only 8.8, but
signiﬁcantly higher than in the control group. Interest-
ingly, ESS and global PSQI score were correlated only in
(female) CMT patients with RLS, which may be
explained by two circumstances: First, the PSQI reﬂects
sleep quality rather than restorativeness of sleep. Second,
poor sleep and excessive daytime sleepiness may go
together only in the presence of a condition which mas-
sively reduces sleep quality. In many CMT patients, this
condition is likely to be RLS. A substantial number of
patients with RLS show periodic limb movements during
sleep (PLMS) on polysomnography (PSG), possibly add-
ing to sleep impairment [37, 38]. Gemignani et al. [5]
reported that two-thirds of the CMT2 patients with RLS
they studied had PLMS. Additional PSG studies are
needed to further elucidate the impact of PLMS in CMT.
Disordered breathing during sleep may also be respon-
sible for non-restorative sleep in CMT patients [39].
Phrenic neuropathy and nocturnal hypoventilation have
been described in severely affected individuals [7, 8]. We
and others reported sleep apnea in a high percentage of
patients with CMT1A [9, 10]. Most patients mainly had
obstructive apneas, probably caused by pharyngeal neu-
ropathy and increased upper airway compliance. Future
PSG studies should address this issue by evaluating pha-
ryngeal function. Sleep apnea syndrome is a prominent
cause of excessive daytime sleepiness. Since in our study
ESS scores did not differ signiﬁcantly between the CMT1
and CMT2 subgroups, it will be especially important to
investigate the contribution of obstructive sleep apnea to
daytime sleepiness in CMT2 patients.
It is a limitation of our study that objective clinical
data on neurological impairment were not available. This
fact is inherent to the survey approach we chose, and it
makes it impossible to support the assumption that sleep-
related symptoms are correlated with disease severity in
CMT, as we showed before in a small group of CMT1A
patients with OSA [10]. For this purpose, standardized
scoring tools such as the CMT neuropathy scale should be
applied in future studies [40]. For the beneﬁt of a large
study population, we put up with the fact that the genetic
diagnosis of participants could not be veriﬁed. The
unexpected small number of individuals with CMTX
indicates that self-reported data on genetic diagnoses have
to be interpreted carefully, making it difﬁcult to ascertain
differences between CMT subgroups. However, the per-
centage of participants who reported having CMT1 or
CMT2 appears to be in accordance with the estimated
prevalence of the most common CMT subtypes [1].
Keeping these aspects in mind, it is the quintessence of
our survey that HRQoL is markedly reduced in CMT
patients, which is in keeping with previous reports
[41, 42]. This may be due to excessive daytime sleepiness,
substantial fatigue, poor sleep, and the presence of RLS in
particular. Since causative treatment for CMT is not
available, therapy should not be restricted to physiother-
apy, walking aids and proper foot care. Patients should be
asked for sleep-related symptoms and fatigue in order to
identify treatable conditions. Apnea screening is appro-
priate in patients with at least moderate disability, and
PSG should initially be performed if severe RLS, PLMS
or nocturnal hypoventilation are suspected.
J Neurol (2010) 257:646–652 651
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